D-0032-2021 Class II Terminated

Recalled by Direct Rx — Dawsonville, GA

FDA drug recall D-0032-2021 was initiated by Direct Rx on Mar 12, 2019 and is designated Class II. Reason for recall: CGMP deviation: Trace amounts of impurity detected to be N-Methylnitrosobutyric acid (NMBA) in the API. The recall status is terminated (terminated Sep 21, 2021). Affected quantity: 33 bottles.

Recall details

Product Type
Drugs
Report Date
Oct 7, 2020
Initiation Date
Mar 12, 2019
Termination Date
Sep 21, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
33 bottles

Product description

Losartan Pot/HCTZ 50/12.5 mg 90 Tabs Packaged and Distributed By: Direct Rx Dawsonville, GA 30534 Mfg For: Torrent Pharma, Inc. Basking Ridge, NJ 07920 NDC 61919-040-90

Reason for recall

CGMP deviation: Trace amounts of impurity detected to be N-Methylnitrosobutyric acid (NMBA) in the API.

Distribution pattern

FL

Code information

Lot: 12DE1806 Exp. 01/31/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0032-2021
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0032-2021. Report a data issue: hello@regdatalab.com.